08 Jun 2021 --- Growth in China’s infant nutrition industry is currently being driven by value and premiumization rather than volume, meaning that the country’s recent shift toward allowing couples to have up to three children is unlikely to have a significant impact on the infant nutrition sector. NutritionInsight takes a closer look at the latest moves in this space, which include Reckitt Benckiser Group’s sale of its Infant Formula and Child Nutrition (IFCN) business in China at a £2.5 billion (US$3.5 billion) loss. China-based Primavera Capital Group will buy the business for an implied enterprise value of US$2.2 billion.
